Evaluation of Maxy-G34 in Breast Cancer Patients Treated With TAC (Docetaxel, Adriamycin, Cyclophosphamide) Chemotherapy
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Chemotherapy-Induced Neutropenia|Breast Cancer
Interventions: BIOLOGICAL: Maxy-G34
Sponsor: Maxygen Holdings Ltd.
Collaborators: Maxygen ApS|Maxygen, Inc.|Parexel